Apogee CMO sells 5,500 shares after option exercise
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported an option exercise and related stock sale.
Rhea-AI Filing Summary
Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported an option exercise and related stock sale. He exercised stock options covering 4,125 shares of common stock at $22.86 per share, then sold 5,500 shares in an open-market transaction at $78.71 per share.
Following these transactions, he directly holds 205,648 shares of common stock and retains stock options representing the right to purchase 118,915 shares, expiring on December 18, 2033. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025, and represents a small portion of his overall holdings.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Dambkowski Carl
Role
Chief Medical Officer
Sold
5,500 shs ($433K)
Approx. gross sale proceeds
$433K
Approx. exercise cost
$94K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 4,125 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,125 | $22.86 | $94K |
| Sale | Common Stock | 5,500 | $78.71 | $433K |
Holdings After Transaction:
Stock Option (Right to Buy) — 118,915 contracts (Direct);
Common Stock — 205,648 shares (Direct)
Footnotes (2)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
- F2. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.
Key Figures
Shares sold: 5,500 shares
Sale price: $78.71/share
Options exercised: 4,125 shares
+5 more
8 metrics
Shares sold
5,500 shares
Open-market sale of common stock at $78.71 on June 3, 2026
Sale price
$78.71/share
Price per share for 5,500 common shares sold
Options exercised
4,125 shares
Stock options converted into common stock at $22.86
Option strike price
$22.86/share
Exercise price for 4,125 stock options
Common shares held
205,648 shares
Direct ownership after sale on June 3, 2026
Remaining option rights
118,915 shares
Stock Option (Right to Buy) after exercise, expiring December 18, 2033
Option expiration
December 18, 2033
Expiration date of stock option grant
10b5-1 plan adoption
September 22, 2025
Adoption date of Rule 10b5-1 trading plan governing the sale
Key Terms
Rule 10b5-1 trading plan, open-market sale, Stock Option (Right to Buy), vest in forty-eight equal monthly installments, +1 more
5 terms
Rule 10b5-1 trading plan financial
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) with underlying security title Common Stock"
vest in forty-eight equal monthly installments financial
"which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service"
expiration date financial
"expiration_date: 2033-12-18T00:00:00.000Z for the stock option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Apogee Therapeutics (APGE) insider Carl Dambkowski do in this Form 4?
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, exercised stock options for 4,125 shares at $22.86 and sold 5,500 shares at $78.71. After these transactions, he continues to hold 205,648 common shares plus a large remaining option position.
What stock options did the Apogee Therapeutics (APGE) CMO exercise in this filing?
He exercised stock options covering 4,125 shares of Apogee Therapeutics common stock at a strike price of $22.86 per share. These options are part of a larger grant that vests monthly through December 18, 2027, tied to his continued service.
What option position does the Apogee Therapeutics (APGE) CMO retain after exercising options?
Following the exercise, he retains stock options representing the right to purchase 118,915 shares of Apogee Therapeutics common stock. These options expire on December 18, 2033 and vest in forty-eight equal monthly installments through December 18, 2027.
Was the Apogee Therapeutics (APGE) insider sale made under a Rule 10b5-1 plan?
Yes. The open-market sale of 5,500 shares was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. Such plans pre-schedule trades, making the timing more routine rather than a discretionary market-timing decision.
AI-generated analysis. How Rhea-AI works. Not financial advice.
